News
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
16h
Pharmaceutical Technology on MSNFDA accepts Novo Nordisk’s NDA submission for weight management therapyThe US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...
Gold edged higher in Asia amid losses in U.S. stock-index futures. The precious metal's direction is likely to be determined by equities' direction and risk appetite, said Fawad Razaqzada, a market ...
Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...
This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...
Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...
Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...
A decision is expected in the fourth quarter of 2025.
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results